Contact information: Becky (877) 643-9040
Send us a confidential email: firstname.lastname@example.org
This clinical trial is for HIV-negative men who have sex with men who may be at risk of
becoming infected with HIV.
Pre-exposure prophylaxis (PrEP) is a promising strategy of using HIV medications to
prevent HIV transmission in HIV-negative people who are at high risk of becoming
infected with HIV. This study will evaluate the safety and tolerability of 4 antiretroviral
(ARV) regimens in preventing HIV in men who have sex with men and transgender
The antiretroviral drugs used in the study are maraviroc, emtricitabine and tenofovir and
are all taken as pills. They are FDA-approved to treat HIV infection but are not approved
for PrEP. The study will help determine if these drugs are safe to take in people who are
not HIV-positive, and the study will also evaluate how well HIV-negative people tolerate
taking the drugs.
For more information, visit the NextPrep Site: http://nextprepstudy.org/faqs.html